Oncogenex Pharma (OGXI) 0.55 $OGXI Biotech Stock

New Post Public Reply Private Reply Replies (0) Message Board

Sep 1, 2016 at 11:06 PM

Oncogenex Pharma (OGXI) 0.55 $OGXI

Biotech Stock Roundup: Vertex Slips on Study Halt, Aurinia Plunges on Lupus Data
Arpita Dutt - Zacks Investment Research - Wed Aug 17, 2:49PM CDT
With second quarter earnings season drawing to a close, focus in back on pipeline and regulatory updates.
BIIB: 306.03 (+0.40), VRTX: 94.75 (+0.24), AUPH: 1.95 (+0.01), OGXI: 0.55 (+0.01), GILD: 77.42 (-0.96), AVEO: 0.91 (-0.02), AMGN: 170.13 (+0.07)

OncoGenex Down on Poor Phase III Data on Lead Cancer Drug
Zacks Equity Research - Zacks Investment Research - Wed Aug 17, 8:57AM CDT
Shares of OncoGenex Pharmaceuticals, Inc. (OGXI) were down 41% after the company announced disappointing data from its late-stage trial, AFFINITY, on custirsen in men with metastatic castrate-resistant prostate cancer.
OGXI: 0.55 (+0.01), ANIP: 61.42 (+1.68), CORT: 5.35 (+0.02), PCRX: 40.37 (+0.74)

OncoGenex Announces Results from the Phase 3 AFFINITY Trial of Custirsen in Men with Metastatic Castrate-Resistant Prostate Cancer
CNW Group - Tue Aug 16, 6:00AM CDT
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today results from the final analysis of AFFINITY, the Phase 3 trial of custirsen in men with metastatic castrate-resistant prostate cancer (CRPC) whose disease has progressed after treatment with docetaxel. The trial did not meet the primary endpoint of demonstrating a statistically significant improvement in overall survival for patients treated with custirsen in combination with cabazitaxel/prednisone compared to cabazitaxel/prednisone alone.
OGXI: 0.55 (+0.01)

OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Second Quarter 2016
PR Newswire - Thu Aug 04, 3:01PM CDT
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced its second quarter 2016 financial results and provided a summary of anticipated milestones.
OGXI: 0.55 (+0.01)

Rexahn's Drugs Deal a Death Blow to Solid Tumor Cancer
ACCESSWIRE - Thu May 19, 8:01AM CDT
Efficacy in Gemzar-resistant cancer is proven
RNN: 0.25 (unch), OGXI: 0.55 (+0.01), AMGN: 170.13 (+0.07), LLY: 77.23 (-0.52), BMY: 56.76 (-0.63), MNTA: 12.15 (+0.13), CELG: 106.37 (-0.37), EXEL: 11.35 (+0.20)

OncoGenex Pharmaceuticals, Inc. Reports Financial Results for First Quarter 2016
PR Newswire - Thu May 12, 3:01PM CDT
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced its first quarter 2016 financial results and provided a summary of anticipated milestones.
OGXI: 0.55 (+0.01)

OncoGenex to Report First Quarter 2016 Financial Results on May 12, 2016
PR Newswire - Thu Apr 28, 3:01PM CDT
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that it will report its first quarter 2016 financial results on Thursday, May 12, 2016. Company management will host a conference call and live webcast at 4:30 p.m. Eastern Time to provide an overview of financial results, clinical development programs and a general corporate update.
OGXI: 0.55 (+0.01)

Analyst Review and Estimates; OncoGenex Pharmaceuticals Inc. (NASDAQ: OGXI)
ACCESSWIRE - Tue Apr 26, 1:05PM CDT
BOTHELL, WA and VANCOUVER, BC / ACCESSWIRE / April 26, 2016 / OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) is a clinical-stage biopharmaceutical company engaged in the development and commercialization of therapies that address treatment resistance in cancer patients. The Company's segment is dedicated to the development and commercialization of cancer therapies, with operations located in Canada and the United States. The Company's product candidates include Custirsen, Apatorsen and OGX-225. The Company is focused on targeting these particular proteins to disable the tumor cell's adaptive defenses, thereby rendering the tumor cells susceptible to attack with a range of cancer therapies. Of these product candidates, Custirsen and Apatorsen are clinical-stage assets. Custirsen is being evaluated in two Phase III trials. Apatorsen is a product candidate designed to inhibit production of heat shock protein 27 (Hsp27). OGX-225 is a product candidate designed to inhibit the production of Insulin Growth Factor Binding Proteins-2 and -5 (IGFBP-2, IGFBP-5). There are a several analyst covering OGXI's securities. The focus of the following report is several analyst rating and the companies drug pipeline and progress.
OGXI: 0.55 (+0.01)

Trending Stocks: Four of Wall Street's Most Active Equities on April 26, 2016
ACCESSWIRE - Tue Apr 26, 11:12AM CDT
MIAMI, FL / ACCESSWIRE / April 26, 2016 / Top Nasdaq Stocks is issuing a report on four stocks to watch. OGXI, LPTN, UPL, and CPLP have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks on the Nasdaq/NYSE subscribe to our newsletter at TopNasdaqStocks.com.
OGXI: 0.55 (+0.01), UPL: 0.31 (unch), CPLP: 3.52 (-0.03), LPTN: 2.37 (+0.02)

These 4 Small Cap Stocks Are Having Big Volume Days Today
ACCESSWIRE - Tue Apr 26, 9:38AM CDT
NEW YORK, NY / ACCESSWIRE / April 26, 2016 / The Stock Expert is issuing a report on four stocks that are performing well this Tuesday. SEED, OGXI, NVIV and TCS are on high volume alert. Continue reading to find out why. - To get daily alerts on the hottest stocks on the Nasdaq/NYSE subscribe to our newsletter at TheStockExpert.com.
NVIV: 6.89 (-0.15), OGXI: 0.55 (+0.01), SEED: 2.20 (-0.02), TCS: 5.35 (+0.03)

OncoGenex Pharmaceuticals to Present at the 15th Annual Needham Healthcare Conference
PR Newswire - Tue Apr 05, 3:02PM CDT
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that John Bencich, Chief Financial Officer at OncoGenex, will present at the 15th Annual Needham Healthcare Conference on April 13, 2016 at the Westin Grand Central Hotel in New York City.
OGXI: 0.55 (+0.01)

OncoGenex Announces Reduction in Force to Extend Cash Runway and Align Operations with Clinical Development Priorities
CNW Group - Thu Feb 04, 3:01PM CST
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that it is implementing a plan to reduce operating expenses, including a workforce reduction of approximately 27%. The Company expects cost savings associated with the reduction of employees and consultants, together with the elimination of certain planned expenditures not required for the completion of ongoing trials, will extend cash runway into the third quarter of 2017.
OGXI: 0.55 (+0.01)

OncoGenex Cancer Drug Fails to Show PFS in Phase II Trial
Zacks Equity Research - Zacks Investment Research - Thu Jan 21, 11:50AM CST
OncoGenex Pharmaceuticals, Inc. (OGXI) announced that apatorsen failed to achieve the primary endpoint in an ongoing mid-stage study for NSCLC.
IMDZ: 7.11 (+0.06), EARS: 1.71 (-0.14), OGXI: 0.55 (+0.01), CORT: 5.35 (+0.02)

OncoGenex Announces Update on Phase 2 Spruce Trial in Previously Untreated Metastatic Non-Small Cell Lung Cancer
PR Newswire - Wed Jan 20, 3:01PM CST
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that data from the Phase 2 Spruce(TM) trial evaluating the combination of apatorsen with carboplatin and pemetrexed in patients with untreated metastatic non-small cell lung cancer (NSCLC) did not reach the statistical significance required to demonstrate a progression-free survival (PFS) benefit. A potential PFS benefit was observed in patients with high baseline serum Hsp27 status when treated with apatorsen. The study is ongoing and overall survival results are expected in the second half of 2016.
OGXI: 0.55 (+0.01)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

BeyondCPG Accelerator Launches Seventh Growth Program

Fresh Faces in Conscious Consumerism There's nothing quite like an early morning jolt of caffeine mixed with the buzz of innovation in the air. BeyondCPG, a heavyweight in the conscious products arena, has cracked open the doors to its seventh round of powerhouse brand-boosting with the launch of its new Accelerator Track 7. They're mixing heart with hustle to give...

illycaffè's B Corp™ Recertification Reflects Bold Commitment

illycaffè Hits Milestone with B Corp™ Recertification In an era where corporate responsibility isn't just fodder for feel-good presentations, illycaffè has proven it’s not just paying lip service to the idea. The Italian coffee titan has secured its B Corp™ recertification under snazzier, sharper V2 standards. This isn't just a shiny sticker to slap on marketing...

Seatrium, Karpowership Wrap Landmark FSRU Partnership

A Milestone in Global Energy Infrastructure Out of Admiralty Yard in Singapore comes a transformation saga that’s begging for attention. Seatrium Limited and Karpowership have pulled off something spectacular with their seventh and final Floating Storage and Regasification Unit (FSRU), LNGT Türkiye. It's not just another vessel hitting the waters—it's the bookend on...

Subaru, Motorq Offer Hardware-Free Fleet Telematics Insights

An Unplugged Move in Fleet Management There's something brewing between Motorq and Subaru that could shake up fleet operations in ways most haven't thought possible yet. We’re talking about cutting those pesky hardware cords and diving straight into a future that's software-driven—and hey, we're all here for it. Direct, Data-Driven Leadership Imagine you're a fleet...

Quantum Sky's Strategic Leadership Overhaul Targets Growth

Executive Shake-Up Aims for Stronger Federal Market Alignment Buckle up, folks—there's some major chess-piecing happening at Quantum Sky. They've just named not one or two, but three executive bigwigs to head up their core business groups. This isn’t just some ceremonial reshuffle. Nah, it’s bigger. They're redefining how they tackle the Department of War, Intel &...

Aviator Nation Teams with NFL for 2026 Collection Launch

In a move blending sports with a dash of retro flair, Aviator Nation's dropping its first NFL-licensed collection. They’re looking to serve up a blend of vintage vibes and team spirit. Aviator Nation's New Venture Launching their collection on September 24th, 2026, Aviator Nation takes a dive deeper into sports licensing, after scoring a touchdown (literally!) with an...

VERTESS Tops Axial's 2026 Healthcare M&A Advisor List

Strength Takes Top Spot in Healthcare M&A VERTESS has grabbed the gold medal in healthcare sell-side M&A, something that didn't just fall from the sky. Axial gave them the nod as the cream of the crop among the Top 50 Lower Middle Market Healthcare M&A Advisors for 2026. Evaluating the Strengths that Set VERTESS Apart When Axial, that private deal network that's all about...

United Apartment Group's Leadership Revamp Signals Growth

A Bold Leadership Expansion Big moves are afoot at United Apartment Group (UAG). They're not just refilling some roles here; they're rebooting their lineup with serious hitters—Woody Stone and Lenzie O’Connor are now steering the ship on business development and client services, eager to drive the company to new heights. Woody Stone: Fueled by Experience Stone isn't...

Lincoln Educational Services Faces Securities Fraud Suit

A Storm Brews Over Lincoln Educational Services You know, there's nothing quite like the stink of a good mess in the markets, and Lincoln Educational Services Corporation has found itself knee-deep in one. The buzz is all about some securities fraud allegations that could rope in a bunch of investors who got the short end of the stick. It’s lawsuits like these that make...

NSF Backs New Space Projects: Cooling & Drug Delivery

You know, every time we think we're at the edge of current science, space reminds us how little we actually know. From the International Space Station up there in low Earth orbit, fresh experiments are kicking off to change what we understand about electronics cooling and drug delivery. It's a classic scenario of reaching for the stars to help us out back here on Earth....